



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT
Attorney Docket No.: 015280-356100US
Client Ref. No.: E-201-98/2

U.S. Patent and Trademark Office
Box SEQUENCE
P.O. Box 2327
Arlington, VA 22202

On Dec. 5, 2002

TOWNSEND and TOWNSEND and CREW LLP

By: Patricia Anders

11/13
JW
12/18/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

PASTAN *et al.*

Application No.: 09/673,707

Filed: January 11, 2001

For: RECOMBINANT IMMUNOTOXIN
DIRECTED AGAINST THE HIV-1
GP120 ENVELOPE GLYCOPROTEIN

Examiner: Zeman, Robert A.

Art Unit: 1645

COMMUNICATION UNDER

37 C.F.R. §§ 1.821-1.825

AND

AMENDMENT

RECEIVED

DEC 16 2002

TECH CENTER 1600/2000

U.S. Patent and Trademark Office
Box SEQUENCE
P.O. Box 2327
Arlington, VA 22202

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, that accompanied the Office Communication mailed November 5, 2002, Applicants submit herewith the required paper copy and computer readable copy of the Sequence Listing. Applicants also take this opportunity to correct some typographical errors noted in the course of preparing the Sequence Listing.

In accordance with 37 C.F.R. §§ 1.821-1.825, please amend the specification as follows.